摘要
一氧化氮(NO)是一种信号基、高扩散性的多效性调节大量不同的分子生物学通路,包括神经递质、血管扩张和抗感染的宏观噬菌体介导的反应。它是由氨基酸L-精氨酸和氧通过三种亚型一氧化氮合酶(NOS)的酶的作用产生的,并在组织中得到不同的表达和调节。 越来越多的证据表明,在不同的病理条件下包括癌症都有NO的广泛作用。这种分子双重作用作为一个亲和抗致瘤性的介质已被报道。此外,NO通过作为一个效应分子调节先天免疫反应和作为适应性免疫成分的调节器而发挥着许多的免疫效果。 本文回顾了多种信号分子在肿瘤生物学领域的最新进展,对免疫调节、NO效应物的活性和氮分子(RNS)进行了简洁的描述。特别是,我们总结了最近NO在癌症发病机制中的复杂功能的分子机制。我们还将针对新兴的由NO调节的免疫介导机制,为控制癌症过程并能被NO 影响的复杂的细胞相互作用提供全面的观点。
关键词: 一氧化氮,RNS,肿瘤,免疫逃逸,TAM,MDSCs,一氧化氮供体,微环境,化学免疫治疗。
Current Medicinal Chemistry
Title:Immunoregulatory and Effector Activities of Nitric Oxide and Reactive Nitrogen Species in Cancer
Volume: 23 Issue: 24
Author(s): Cinzia Fionda, Maria Pia Abruzzese, Angela Santoni, Marco Cippitelli
Affiliation:
关键词: 一氧化氮,RNS,肿瘤,免疫逃逸,TAM,MDSCs,一氧化氮供体,微环境,化学免疫治疗。
摘要: Nitric Oxide (NO) is a signaling radical, highly diffusible pleiotropic regulator of a large set of different molecular and biological pathways, including, neurotransmission, vasodilatation and macrophagemediated responses against infections. It is produced from the amino acid L-Arginine and oxygen by the enzymatic action of three isoforms of the Nitric Oxide Synthase (NOS), differently expressed and regulated in tissues.
Increasing evidence highlights the wide spectrum of action of NO in different pathologic conditions, including cancer. In this regard, a dual role for this molecule as a pro- and anti-tumorigenic mediator has been described, in a context and concentration-dependent manner. Moreover, NO exerts numerous immunologic effects, by operating as an effector molecule in innate immune responses as well as a regulator of adaptive immune components.
Here, we will review recent advances in the field of biology of this pleiotropic signaling molecule in cancer, also providing a concise description of the immunoregulatory and effector activities of NO and Reactive Nitrogen Species (RNS). In particular, we will summarize recent knowledge of the molecular mechanisms underlying the complex functions of NO in cancer pathogenesis. We will also address emerging immune-mediated mechanisms regulated by NO to provide a comprehensive view of the complex cellular interactions which control cancer progression and that can be influenced by NO at multiple levels. In the light of different immunologic effects of this molecule, the potential therapeutic implications of novel drugs targeting NO to treat cancer and to improve anti-tumor immune responses will be discussed.
Export Options
About this article
Cite this article as:
Cinzia Fionda, Maria Pia Abruzzese, Angela Santoni, Marco Cippitelli , Immunoregulatory and Effector Activities of Nitric Oxide and Reactive Nitrogen Species in Cancer, Current Medicinal Chemistry 2016; 23 (24) . https://dx.doi.org/10.2174/0929867323666160727105101
DOI https://dx.doi.org/10.2174/0929867323666160727105101 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microbial Biotransformation: Recent Developments on Steroid Drugs
Recent Patents on Biotechnology Cardioprotective Potential of Iron Chelators and Prochelators
Current Medicinal Chemistry Controversies in Glaucoma: Current Medical Treatment and Drug Development
Current Pharmaceutical Design Predictive In Silico Studies of Human 5-hydroxytryptamine Receptor Subtype 2B (5-HT2B) and Valvular Heart Disease
Current Topics in Medicinal Chemistry Atypical Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children: A Systematic Review
Current Pediatric Reviews Hydrogen Sulfide: A New Tool to Design and Develop Drugs
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Development of Mucoadhesive Patches for Buccal Administration of Carvedilol
Current Drug Delivery Beta Blocker Use After Acute Myocardial Infarction in the Patient with Normal Systolic Function: When is it “Ok” to Discontinue?
Current Cardiology Reviews Pharmacovigilance and the Cardiovascular System: Two Sides to Every Story
Current Drug Safety Potential New Targets for Antithrombotic Therapy
Current Pharmaceutical Design Pulmonary Hypertension in COPD: Pathophysiology and Therapeutic Targets
Current Drug Targets Toll-like Receptor 4 Mediates LPS-Induced Release of Nitric Oxide and Tumor Necrosis Factor-α by Embryonal Cardiomyocytes: Biological Significance and Clinical Implications in Human Pathology
Current Pharmaceutical Design A Brief Overview on Chemistry and Biology of Benzoxepine
Letters in Drug Design & Discovery Metabolic Fate of Endocannabinoids
Current Neuropharmacology Development and Validation of a UPLC-MS/MS Method for the Simultaneous Determination of Verapamil and Trandolapril in Rat Plasma: Application to a Pharmacokinetic Study
Current Pharmaceutical Analysis Renin-Angiotensin-Aldosterone System in Autosomal Dominant Polycystic Kidney Disease
Current Hypertension Reviews Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug
Current Diabetes Reviews Aldosterone Receptor Antagonists and Cardiovascular Disease: Do We Need a Change of the Guard?
Cardiovascular & Hematological Agents in Medicinal Chemistry The Ignored Role of Intraoperative Hypotension in Producing Postoperative Acute Kidney Injury-An Obligatory Appeal for More Preventative Nephrology
Current Hypertension Reviews Cancer-Targeting Multifunctionalized Gold Nanoparticles in Imaging and Therapy
Current Medicinal Chemistry